anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We performed comprehensive analyses of somatic copy number alterations (SCNAs) and gene expression profiles of gastric intramucosal neoplasia (IMN) using array-based methods in 97 intestinal-type IMNs, including 39 low-grade dysplasias (LGDs), 37 high-grade dysplasias (HGDs), and 26 intramucosal carcinomas (IMCs) with stromal invasion of the lamina propria to identify the molecular mechanism of IMN. In addition, we examined gene mutations using gene panel analyses. We used cluster analyses for exclusion of arbitrariness to identify SCNA patterns and expression profiles. IMNs were classified into two distinct subgroups (subgroups 1 and 2) based on SCNA patterns. Subgroup 1 showed a genomic stable pattern due to the low frequency of SCNAs, whereas subgroup 2 exhibited a chromosomal instability pattern due to the high frequencies of SCNAs and TP53 mutations. Interestingly, although the frequencies of LGD and HGD were significantly higher in subgroup 1 than in subgroup 2, IMC was commonly found in both types. Although the expression profiles of specific mRNAs could be used to categorise subgroups 1 and 2, no clinicopathological findings correlated with either subgroup. We examined signalling pathways specific to subgroups 1 and 2 to identify the association of each subgroup with signalling pathways based on gene ontology tree visualisation: subgroups 1 and 2 were associated with haem metabolism and chromosomal instability, respectively. These findings reveal a comprehensive genomic landscape that highlights the molecular complexity of IMNs and provide a road map to facilitate our understanding of gastric IMNs.
The invention comprises compounds of the general formula <FORM:0993156/C2/1> and their non-toxic acid addition salts wherein R1 is a hydrogen atom or a C1- 7-alkyl. A halogenated-C1- 7-alkyl group, a monocyclic aryl group, an alkyl-, halogenor alkoxy-substituted monocyclic aryl group or a monocyclic aryl C1- 7-alkyl group, R2 is a hydrogen atom or a C1- 7-alkyl group and R5 is a bivalent radical which together with the adjoining carbon atoms of the quinolizine radical forms a substituted or unsubstituted benzene or indole radical which may have as substituents C1- 7-alkyl groups and/or C1- 7 alkoxy groups or a combination thereof or a methylenedioxy group and X is =C=O or =CH2 and the preparation thereof by cyclizing by heating under reflux conditions in an inert organic solvent a compound of the formula <FORM:0993156/C2/2> and if desired reducing the oxo group formed. Compounds of the invention where Z=CH2 are also prepared by reduction of the corresponding quinolizium quaternary salt or by reduction with subsequent ring closure of the reaction product of a glutaric aldehyde and tryptamine.  Tetrahydro pyridine derivatives used as starting materials are prepared by reacting 3-R1R2-glutaric anhydrides with a phenyl ethylamine or a tryptamine to give an N-2-R3-3-R1R2-glutaramic acid (where R3 is a substituted phenyl or endolyl residue) and cyclizing this after esterification to give a dihydro pyridine derivative which is reduced.  3-(4-Methylphenyl) glutaric acid anhydride is prepared by reacting 4-methylbenzaldehyde with ethyl acetoacetate to form diethyl 2,4-diacetyl-3-(4-methylphenyl) glutarate, hydrolysing this to give 3-(4-methylphenyl) glutaric acid and forming the anhydride. Similarly are prepared the above 3-R1R2-glutaric anhydrides.  Quaternary quinolizinium salts used as starting materials are prepared by reacting a 31-R1R2-5-bromovalerate with a phenylethylamine or a tryptamine to give a 1-(2-R3-ethyl)-4-R1R2-piperiol-2-one and cyclizing this with phosphorus oxychloride.  Ethyl 5-bromo-3-methyl-valerate is prepared from 3-methyl-5-valerolactone and hydrogen bromide in ethanol.  Ethyl 5-bromo-3-phenyl-valerate is also prepared.
OBJECTIVES: Laryngeal dystonia (LD) is characterized by irregular and involuntary task-specific spasms of the intrinsic laryngeal muscles. There is no curative treatment for it, however, laryngeal botulinum neurotoxin injections (BoNT-I) are considered the standard of care therapy. This study aims to characterize the population of LD patients and to assess the results of laryngeal BoNT-I.
METHODS: A Retrospective cohort study was conducted. Medical records were reviewed for all the patients with LD diagnosis seen in the Voice Unit of the Red de Salud UCChristus between January 2013 and October 2021. Biodemographic, clinical and treatment data were collected. Additionally, a telephonic survey was completed by the patients that underwent laryngeal BoNT-I, including self-reported voice outcomes and Voice Handicap Index 10 (VHI-10).
RESULTS: Of the 34 patients with LD included in the study, 23 received a total of 93 laryngeal BoNT-I and 19 completed the telephone survey. The majority (97%) of the injections corresponded to patients with adductor LD and 3% to abductor LD. Patients received a median of 3 (1-17) injections, with a more frequent cricothyroid approach (94.4%), while the thyrohyoid approach accounted for 5.6% of cases. Most injections were bilateral (96.8%). A significant improvement in the vocal quality and effort was noted after the last injection and the overall BoNT-I treatment (P < 0.001). Similarly, the VHI-10 score improved from a median of 31 (7-40) to 2 (0-19) (P < 0.001) after the last injection. A post-treatment breathy voice was reported in 95% of patients, and dysphagia to liquids and solids in 68% and 21%, respectively.
CONCLUSIONS: Laryngeal BoNT-I is an effective treatment for LD, achieving an improvement in self-reported vocal quality and VHI-10 scores, and a reduction of the self-reported vocal effort. Adverse effects are mild in the majority of cases, constituting a safe and effective therapy for these patients.
Tumor tissue, including soft tissue and/or bone tissue, is harvested from a subject and comminuted. The pulverized tissue is placed in a cassette, which is placed in a receiving chamber of a tumor tissue treatment apparatus. Destroying cancer cells in the pulverized tumor tissue without destroying tumor antigens in the tumor tissue. The cells are cryo-damaged by exposing the cartridge to a cooling fluid, such as liquid nitrogen, optionally using a warming cycle, and optionally using more than one freeze/thaw cycle. The treated tissue and/or cells are then removed from the cassette and reintroduced into the subject after they reach a threshold condition. The treated tissue and/or cells may be reintroduced through the containment sleeve or the reimplantation bag.
In people with the metabolic syndrome, the investigators hypothesize that administration of a single 300 mg dose of a grape seed extract (GSE) will reduce insulin resistance (how well cells in the body can take up and use glucose), oxidative stress, and the amount of oxidized LDL in the blood during a 24 hour period. Each of these can be elevated after eating high fat meals, which are commonly found in the average Western diet. To better assess the impact of these high fat eating patterns, three standardized high fat meals will be served during the study day: breakfast, lunch, and dinner. Measurements in the blood will be assessed at hourly intervals during the 24 hour study day protocol. Additionally, the investigators hypothesize that daily administration of 300 mg of GSE for 30 days will decrease baseline insulin resistance, oxidative stress, and the level of oxidized LDL in the blood when this 24 hour study day protocol is repeated and breakfast, lunch, and dinner are again served.

Insulin resistance will be measured using a comparison of insulin and glucose levels in the blood. Oxidative stress, a measure of inflammation, will be measured by cytokines levels in the blood. The level of oxidized LDL will be measured in the blood. The investigators also plan to undertake a subsidiary pharmacokinetic study on the various polymers which are known to be present in grape seed extracts to determine their bio-availability and their relationship to the biological effects observed.
The present invention relates to an oligopeptide for enhancing osteointegration and osteogenesis. More specifically, it relates to bioactive oligopeptide compounds having the general structural formula (C or K)-(I, K or P)-(I, P or K)-(K or P)-(K, P or S)-(P or S)-(A or S)-(A, P or S)-(A, P or T)-(E, P or T)-(E, L or T)-(E, L or S)-(A, L or S)-(A, I or S)-(A, I or S)-(I, M or S)-(L, M or S)-(C, L or M). The oligopeptide of the present invention is effective in bone filler replacement, vertical treatment and horizontal treatment. By using this invention, the continuous action of the oligopeptide on the surface of an implant treated with a thin film of the same can reduce the time of initial osteointegration. Additionally, an increase in the success rate of surgical operations on osteopenia patients can be achieved by inducing an increase in osteoblasts and function. It is also possible to achieve bone formation when bone mass is insufficient, without bone replacement, leading to a reduction in surgical operation costs.
A 54-year-old woman, who had been menopausal for over two years and had an Intrauterine Device (IUD) in place for over twenty years, requested a removal of the IUD. The IUD was found to be embedded during the removal process. Under ultrasound guidance, a hysteroscopic examination revealed the embedded IUD and additional uterine cavity content. Hysteroscopic removal of the IUD and the foreign body was performed, and the pathology report indicated fibrous tissue with hyaline degeneration. For postmenopausal women with IUDs, early removal is recommended to minimise complications. Hysteroscopic examination should be the first choice for the rare complication of embedded IUDs covered with fibrous tissue, with hysteroscopic removal as the preferred treatment.
AIMS: Hormone receptor-positive (HR)+/HER2- breast cancer (BC) is highly heterogeneous, with PI3K/PTEN/mTOR pathway alterations emerging as possible players within this complexity. We longitudinally tracked PI3K/PTEN/mTOR pathway dynamics from baseline biopsy to residual disease (RD)-and to metastases in case of relapse-in HR+/HER2- BC patients receiving neoadjuvant chemotherapy (NACT).
METHODS: HR+/HER2- BC patients with RD after NACT were identified. We assessed PIK3CA mutational, Pten-loss and phosphorylation levels of mTOR and its substrates (p70S6K and 4EBP1) on baseline biopsies and matched RD samples; in case of disease relapse, we also assessed PIK3CA mutational status on metastatic samples. Recurrence-free survival (RFS) was adopted as endpoint.
RESULTS: 92 patient were included. The conversion rate of PIK3CA mutational status was 12.8%; 1 patient acquired PIK3CA mutation at relapse; the rate of Pten conversion was 33.3%; mTOR phosphorylation levels significantly increased from baseline biopsy to RD, while its substrates significantly decreased. Baseline phosphorylated-mTOR significantly predicted poorer RFS in patients with PIK3CA wild-type status; baseline phosphorylated-70S6K was positively associated with RFS.
CONCLUSIONS: We observed that PI3K/PTEN/mTOR pathway is highly dynamic under NACT exposure and the assessment of PIK3CA mutations may capture only a small fraction of such complexity. In this context, mTOR activation trough alternative pathways with respect to PIK3CA signalling may have a crucial role in shaping the molecular landscape of HR+/HER2- BC with RD after NACT. It is imperative to further elucidate the role of PIK3CA and mTOR-dependent pathways in shaping chemoresistance and endocrine resistance in high-risk HR+/HER2- early/locally advanced BC patients.
Phase 2, proof-of-concept (POC) clinical trial designed to evaluate the safety and efficacy of ocular iontophoretic delivery of dexamethasone phosphate ophthalmic solution compared to ocular iontophoresis with a placebo (100 mM citrate buffer of pH 5.7) in patients planning to have cataract surgery with implantation of a posterior chamber intraocular lens (IOL). The population studied was comprised of males and females scheduled for unilateral cataract surgery with implantation of a posterior chamber IOL. Eligible patients were enrolled into the study and were randomized on Day 1 in a 1:1 ratio into one of the following two treatment arms. Treatments were administered on the day prior (Day -1) to cataract surgery (Day 0). Subjects were scheduled to return to the clinic on Days 1, 7, 14, and 28. All subjects were scheduled to exit the study on Day 28. Subjects were asked to complete a daily pain score assessment questionnaire for the first 14 days post-surgery (Days 0 - 14).
BACKGROUND: Hypoxia-induced myocardial injury remains to be a huge health issue worldwide. Transient receptor potential vanilloid 4 (TRPV4) is a high-flux Ca2+ channel that is involved in numerous cardiovascular diseases. However, the role of TRPV4 in myocardial hypoxic injury remains unclear. Accordingly, this study aimed to investigate the antiapoptotic activity of TRPV4 inhibition and elucidate the underlying mechanisms in myocardial hypoxic injury.
METHODS: The ability of TRPV4 to modulate the endoplasmic reticulum stress (ERS) and apoptosis was assessed in vitro through the administration of the TRPV4 antagonist HC-067047 or the agonist GSK1016790A. Additionally, intracellular Ca2+ concentration was measured by Fluo-4 AM.
RESULTS: TRPV4 expression was significantly upregulated in hypoxic H9c2 cells compared with that in normoxic cardiomyocytes, accompanied with increased intracellular Ca2+ levels. Conversely, TRPV4 inhibition alleviated ERS in hypoxic H9c2 cells and prevented apoptosis, whereas TRPV4 agonist exacerbated such events. Furthermore, H9c2 cell apoptosis was attenuated with the administration of 4-PBA, an ERS inhibitor.
CONCLUSION: TRPV4 inhibition alleviates hypoxia-induced H9c2 cell apoptosis by mitigating ERS.
This study is a non-randomized observational cohort study of participants with XLA who have either received, as standard care, the Pfizer BioNTech BNT162b2 mRNA vaccine or the Moderna mRNA-1273 vaccine. In this protocol, vaccination is entirely voluntary and vaccines are not provided by the study.
Nimesulid inclusin cpds. (I) with betacyclodextrin alpha,beta and gamma or in their aq. are new and/or have molar ratio nimesulid:cyclodextrin 1:0.5 - 1:15. Pref. the cyclodextrin is of beta-type and. USE/ADVANTAGE - (I) shows improved bioavailability and increase the max. plasma concn. of the nimesulid, which is an antiphlogistic used in the treatment of articular and extraarticular inflammations and is very sparingly soluble and of low bioavailability. (I) have analgesic and antiphlogistic properties and are well soluble in water thus ensuring that the nimesulid is more rapidly resorbed. Suitable unit doses contain 20-150 mg (I). (9pp Dwg.No.0/3)
Ten subjects will be administered 15mg PA3670 after overnight fasting for 10 hours in the first cycle, and then will be administered 10mg PA3670 within 30 minutes after high-fat meal in the second cycle. They will receive a single dose in each cycle and will be observed for four days. The cleaning period between the two cycles is more than 7 days.
A peptide-based therapy for a retinal disease, injury or condition in a subject comprising administering to the subject a pharmaceutical composition comprising at least one peptide derived from a heat shock protein comprising Hsp20 and αb-crystalin. The administered peptide may be acetylated and/or conjugated to a cell penetrating peptide. Administration of the peptide may reduce or prevent loss of at least one retinal cell type, including retinal ganglion cells and retinal endothelial cells. Loss of these cells can lead to retinal damage and vision loss in patients with eye diseases. The pharmaceutical composition may be intravitreally administered via a delivery device. A single injection may be therapeutically sufficient to treat a variety of eye diseases.
Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.
Since its introduction in the late 1990s, immediate implant loading concepts (IL) have become a frequent alternative for delayed implant procedures. IL concepts reduce chair time, the number of surgical interventions and pain, and offer instant comfort to the patient. Its reduced treatment time results in obvious socioeconomic advantages. Although there is at present abundant evidence that supports IL, evaluation of long-term biological and mechanical stability outcomes of large patient populations could allow quality improvement and more accurate patient selection. The Departments of Oral and Maxillofacial Surgery and the Department of Dentistry of the General Hospital Saint-John Bruges act as one of the pioneers of IL in Belgium, routinely performing the concept since 2001.

The investigators aim to evaluate the biological and mechanical short- and long-term outcome of IL in partially or completely edentulous patients. Moreover, the investigators aim to detect potential influencing risk factors predicting undesirable prosthetic outcome.
INTRODUCTION: Takotsubo cardiomyopathy (TCM) features transient left ventricular apical dysfunction or ballooning. The underlying mechanism remains elusive; however, evidence suggests the role of different physical and psychological stressors. We systematically reviewed patients presenting with TCM and autoimmunity to explore the link between the two conditions.
METHODS: We applied the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) to report this review. Using keywords related to autoimmune/immune-mediated diseases and TCM, we searched PubMed, Scopus, and WOS in March 2022. The final results were added to a data extraction sheet. Data were analyzed by SPSS version 26.0.
RESULTS: Our search yielded 121 studies, including 155 patients. Females were considerably predominant. Most patients had a history of autoimmune disease, and almost a third had a history of cardiovascular disease. Dyspnea and chest pain were the most common chief complaints. More than 70% of patients had experienced physical stress. Myasthenia gravis, systemic lupus erythematosus, and multiple sclerosis were the most frequently reported autoimmune diseases.
CONCLUSION: There were similarities in age and sex compared to classic TCM. TCM should be considered as a differential diagnosis for ACS, especially in patients with a positive background of autoimmunity. A precise reporting system is required for further studies.
In a method and arrangement for allocating prosthetic installation work between at least three parties (A, B, C) a dental situation and fixture application are simulated on a computer screen by the first party. The second party produces first components in connection with the prosthetic installation with the aid of a recording and said simulation. Second components are supplied by the third party (C) and the prosthetic installation is assembled and fitted by the first party by means of said first and second components.  The recording includes first and second readings of a loose prosthesis and a portion supporting the prosthetic insallation. The simulation includes collation of representations of the readings on a computer screen. Simulated fixture applications are constructed and a model is produced by one of said parties, or a fourth party. An assembly template guides hole-forming members in an actual substrate in directions which correspond to the directions of the fixtures. A dental bridge is provided with attachment holes which connect to the holes formed in the substrate. Fixtures are applied in said formed holes by the first party and the dental bridge is secured in or on said fixtures.  The invention also relates to a computer program in connection with the above.
The invention relates to compositions in gel form, with an increased content of electrolyte and use thereof as support media for oxidative dyes. The gel composition comprises 6.0 to 15 wt. % of a saturated or unsaturated linear or branched 8-36 C alcohol, 0.1 to 15 wt. % of a liquid 16-22 C fatty acid in the form of a water-soluble soap, 0.5 to 10 wt. % of an addition product of 1 to 5 Mol ethylene oxide to a linear 8-22 C fatty alcohol, 0.5 to 10 wt. % of an addition product of 15 to 50 Mol ethylene oxide to a linear 8-22 C fatty alcohol, 0 to 20 wt. % of a low-molecular weight water-soluble alcohol and not less than 12 mmol of an electrolyte, based on 100 g of the gel composition, characterised by excellent application properties and an improved shelf life.
Acalabrutinib will be orally administered until disease progression or unacceptable toxicity. Rituximab IV infusions will be administered weekly for 4 weeks and on Day 1 of Cycle 3 through 8, and thereafter every other cycle for less than or equal to two years (approximately 200 subjects).
The present invention relates to a UV-curable manicure of which a color is changed by light and the temperature. The manicure comprises: a base coat (a base layer) applied on the bottom in order to protect a nail; a color gel (a color layer) of which a color is changed by various pigments; and a top coat (a top layer) on the top which protects the nail and the color gel and provides glossiness to the nail. According to the present invention, the curing speed is reduced to two minutes or shorter; a step of cleaning the nail with a gel cleaner can be skipped; and the manicure can be soaked-off with 15 minutes or shorter. Therefore, complicated UV curable manicure application processes can be reduced. The manicure can be manufactured in the form of a sticker and thus can be applied for nail polishing in an easy manner. The manicure in the form of a sticker can be attached to an object such as a mobile phone and thus can be widely applied.